menu
    • menu
    [{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Salsalate","moa":"anti-inflammatory agents (salicylic acid derivatives); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Kuhnil Pharmaceutical, Co. Ltd"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Neurim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"KI1001","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Neurim Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Neurim Pharmaceuticals"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Neurim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KI1001","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Neurim Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Neurim Pharmaceuticals"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"KI1106","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"KI1107","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Kuhnil Pharmaceutical, Co. Ltd

    Menu

    Kuhnil Pharmaceutical, Co. Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KI1106

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorva...

                            Details : KI1106 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 29, 2018

                            Lead Product(s) : KI1106

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : KIMJisun

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2017

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : KIMJisun

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salsalate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase IV

                            Recipient : Korea University Guro Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

                            Details : Salsalate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2017

                            Lead Product(s) : Salsalate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase IV

                            Recipient : Korea University Guro Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KI1107

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuva...

                            Details : KI1107 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 20, 2017

                            Lead Product(s) : KI1107

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson D...

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of REM Sleep Behavior Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 03, 2016

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2016

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 ...

                            Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2014

                            Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KI1001

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Neurim Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

                            Details : KI1001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 14, 2014

                            Lead Product(s) : KI1001

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Neurim Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type â…¡b Hyperlipide...

                            Details : Atorvastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperlipidemia, Familial Combined.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2014

                            Lead Product(s) : Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Kuhnil Pharmaceutical, Co. Ltd

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesopha...

                            Details : Irinotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2013

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth